{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:17:40Z","timestamp":1792783060390,"version":"4.5.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["2020T058"],"award-info":[{"award-number":["2020T058"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018890","name":"Dutch Cardiovascular Alliance","doi-asserted-by":"publisher","award":["2020B008: RECONNEXT"],"award-info":[{"award-number":["2020B008: RECONNEXT"]}],"id":[{"id":"10.13039\/100018890","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hartstichting, The Netherlands","award":["2020T058"],"award-info":[{"award-number":["2020T058"]}]},{"name":"Dutch Cardiovascular Alliance, The Netherlands","award":["2020B008: RECONNEXT"],"award-info":[{"award-number":["2020B008: RECONNEXT"]}],"id":[{"id":"https:\/\/ror.org\/02e8s5y35","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10671-x","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:42:24Z","timestamp":1789958544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heart failure with a preserved ejection fraction: synergy between cardiac and extracardiac mechanisms and effects of novel therapies"],"prefix":"10.1007","volume":"31","author":[{"given":"Soufiane","family":"Nassiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Louis","family":"Handoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno A.","family":"van de Bovenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa P.M.","family":"van Empel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00ebl H.","family":"van Raalte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etto C.","family":"Eringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"16","key":"10671_CR1","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1093\/eurheartj\/ehae868","volume":"46","author":"BJ van Essen","year":"2025","unstructured":"van Essen BJ, Emmens JE, Tromp J, Ouwerkerk W, Smit MD, Geluk CA et al (2025) Sex-specific risk factors for new-onset heart failure: the PREVEND study at 25 years. Eur Heart J 46(16):1528\u20131536","journal-title":"Eur Heart J"},{"issue":"37","key":"10671_CR2","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M et al (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 44(37):3627\u20133639","journal-title":"Eur Heart J"},{"issue":"1","key":"10671_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","volume":"134","author":"SJ Shah","year":"2016","unstructured":"Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA et al (2016) Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation 134(1):73\u201390","journal-title":"Circulation"},{"issue":"7","key":"10671_CR4","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.111.076075","volume":"126","author":"L van Heerebeek","year":"2012","unstructured":"van Heerebeek L, Hamdani N, Falc\u00e3o-Pires I, Leite-Moreira AF, Begieneman MP, Bronzwaer JG et al (2012) Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 126(7):830\u2013839","journal-title":"Circulation"},{"issue":"8","key":"10671_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.111.085761","volume":"126","author":"M Guazzi","year":"2012","unstructured":"Guazzi M, Borlaug BA (2012) Pulmonary Hypertension Due to Left Heart Disease. Circulation 126(8):975\u2013990","journal-title":"Circulation"},{"key":"10671_CR6","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V et al Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 0(0)"},{"issue":"16","key":"10671_CR7","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS et al (2024) Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 391(16):1475\u20131485","journal-title":"N Engl J Med"},{"issue":"12","key":"10671_CR8","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, Boer RAd, DeMets D, Hernandez AF et al (2022) Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 387(12):1089\u20131098","journal-title":"N Engl J Med"},{"issue":"20","key":"10671_CR9","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS et al (2023) Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation 148(20):1606\u20131635","journal-title":"Circulation"},{"issue":"12","key":"10671_CR10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M et al (2023) Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 389(12):1069\u20131084","journal-title":"N Engl J Med"},{"issue":"6","key":"10671_CR11","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/cvr\/cvaf056","volume":"121","author":"C Janssen-Telders","year":"2025","unstructured":"Janssen-Telders C, Eringa EC, de Groot JR, de Man FS, Handoko ML (2025) The role of epicardial adipose tissue remodelling in heart failure with preserved ejection fraction. Cardiovasc Res 121(6):860\u2013870","journal-title":"Cardiovasc Res"},{"issue":"8","key":"10671_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jchf.2020.04.016","volume":"8","author":"KE Koepp","year":"2020","unstructured":"Koepp KE, Obokata M, Reddy YNV, Olson TP, Borlaug BA (2020) Hemodynamic and Functional Impact of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail 8(8):657\u2013666","journal-title":"JACC Heart Fail"},{"issue":"17","key":"10671_CR13","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jacc.2024.08.028","volume":"84","author":"S Verma","year":"2024","unstructured":"Verma S, Petrie Mark C, Borlaug Barry A, Butler J, Davies Melanie J, Kitzman Dalane W et al (2024) Inflammation in Obesity-Related HFpEF. JACC 84(17):1646\u20131662","journal-title":"JACC"},{"issue":"9","key":"10671_CR14","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","volume":"8","author":"VS Hahn","year":"2020","unstructured":"Hahn VS, Yanek LR, Vaishnav J, Ying W, Vaidya D, Lee YZJ et al (2020) Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. JACC Heart Fail 8(9):712\u2013724","journal-title":"JACC Heart Fail"},{"key":"10671_CR15","doi-asserted-by":"crossref","unstructured":"Wattanachayakul P, Kittipibul V, Yaranov DM, Miller WL, Fudim M (2025) The impact of obesity on pressure-volume relationship in ambulatory heart failure. J Cardiovasc Transl Res 18(5):1395-1397","DOI":"10.1007\/s12265-025-10684-1"},{"issue":"1","key":"10671_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/sj.ki.5002586","volume":"73","author":"Y Wang","year":"2008","unstructured":"Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ (2008) Association between obesity and kidney disease: A systematic review and meta-analysis. Kidney Int 73(1):19\u201333","journal-title":"Kidney Int"},{"issue":"5","key":"10671_CR17","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","volume":"59","author":"AM Briones","year":"2012","unstructured":"Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y et al (2012) Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 59(5):1069\u20131078","journal-title":"Hypertension"},{"issue":"3","key":"10671_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/00000441-200209000-00003","volume":"324","author":"JE Hall","year":"2002","unstructured":"Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM (2002) Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 324(3):127\u2013137","journal-title":"Am J Med Sci"},{"issue":"5","key":"10671_CR19","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.kint.2020.12.013","volume":"99","author":"RP Juni","year":"2021","unstructured":"Juni RP, Al-Shama R, Kuster DWD, van der Velden J, Hamer HM, Vervloet MG et al (2021) Empagliflozin restores chronic kidney disease\u2013induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction. Kidney Int 99(5):1088\u20131101","journal-title":"Kidney Int"},{"issue":"7","key":"10671_CR20","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/0026-0495(95)90251-1","volume":"44","author":"WT Cefalu","year":"1995","unstructured":"Cefalu WT, Wang ZQ, Werbel S, Bell-Farrow A, Crouse JR, Hinson WH et al (1995) Contribution of visceral fat mass to the insulin resistance of aging. Metabolism 44(7):954\u2013959","journal-title":"Metabolism"},{"issue":"1","key":"10671_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","volume":"136","author":"M Obokata","year":"2017","unstructured":"Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA (2017) Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation 136(1):6\u201319","journal-title":"Circulation"},{"issue":"3","key":"10671_CR22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/jdi.13355","volume":"12","author":"H Li","year":"2021","unstructured":"Li H, Lu W, Wang A, Jiang H, Lyu J (2021) Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: Estimates from Global Burden of Disease 2017. J Diabetes Investig 12(3):346\u2013356","journal-title":"J Diabetes Investig"},{"issue":"16","key":"10671_CR23","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M et al (2021) Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 385(16):1451\u20131461","journal-title":"N Engl J Med"},{"issue":"1","key":"10671_CR24","first-page":"1","volume":"6","author":"WJ Paulus","year":"2018","unstructured":"Paulus WJ, Dal Canto E (2018) Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction. JACC: Heart Fail 6(1):1\u20137","journal-title":"JACC: Heart Fail"},{"issue":"1","key":"10671_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","volume":"97","author":"EJM van Bommel","year":"2020","unstructured":"van Bommel EJM, Muskiet MHA, van Baar MJB, Tonneijck L, Smits MM, Emanuel AL et al (2020) The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int 97(1):202\u2013212","journal-title":"Kidney Int"},{"issue":"9","key":"10671_CR26","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.2337\/dc09-0206","volume":"32","author":"MA Keske","year":"2009","unstructured":"Keske MA, Clerk LH, Price WJ, Jahn LA, Barrett EJ (2009) Obesity blunts microvascular recruitment in human forearm muscle after a mixed meal. Diabetes Care 32(9):1672\u20131677","journal-title":"Diabetes Care"},{"issue":"10","key":"10671_CR27","first-page":"e009124","volume":"15","author":"EB Winzer","year":"2022","unstructured":"Winzer EB, Augstein A, Schauer A, Mueller S, Fischer-Schaepmann T, Goto K et al (2022) Impact of Different Training Modalities on Molecular Alterations in Skeletal Muscle of Patients With Heart Failure With Preserved Ejection Fraction: A Substudy of the OptimEx Trial. Circulation: Heart Fail 15(10):e009124","journal-title":"Circulation: Heart Fail"},{"issue":"11","key":"10671_CR28","first-page":"e010618","volume":"16","author":"MF Ramirez","year":"2023","unstructured":"Ramirez MF, Lau ES, Parekh JK, Pan AS, Owunna N, Wang D et al (2023) Obesity-Related Biomarkers Are Associated With Exercise Intolerance and HFpEF. Circulation: Heart Fail 16(11):e010618","journal-title":"Circulation: Heart Fail"},{"issue":"12","key":"10671_CR29","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.2337\/dc11-1039","volume":"34","author":"K Hanai","year":"2011","unstructured":"Hanai K, Babazono T, Mugishima M, Yoshida N, Nyumura I, Toya K et al (2011) Association of Serum Leptin Levels With Progression of Diabetic Kidney Disease in Patients With Type 2 Diabetes. Diabetes Care 34(12):2557\u20132559","journal-title":"Diabetes Care"},{"key":"10671_CR30","doi-asserted-by":"crossref","unstructured":"Kono T, Maimaituxun G, Tanabe H, Higa M, Saito H, Tanaka K et al (2024) Role of perirenal adiposity in renal dysfunction among CKD individuals with or without diabetes: a Japanese cross-sectional study. BMJ Open Diabetes Res Care. 12(2):e003832","DOI":"10.1136\/bmjdrc-2023-003832"},{"issue":"5","key":"10671_CR31","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1381\/0960892053923734","volume":"15","author":"M Ruano","year":"2005","unstructured":"Ruano M, Silvestre V, Castro R, Garc\u00eda-Lesc\u00fan MC, Rodr\u00edguez A, Marco A et al (2005) Morbid obesity, hypertensive disease and the renin-angiotensin-aldosterone axis. Obes Surg 15(5):670\u2013676","journal-title":"Obes Surg"},{"issue":"2","key":"10671_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.molmet.2013.11.006","volume":"3","author":"A Stirban","year":"2014","unstructured":"Stirban A, Gawlowski T, Roden M (2014) Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms. Mol Metab 3(2):94\u2013108","journal-title":"Mol Metab"},{"issue":"1","key":"10671_CR33","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/ijms23010531","volume":"23","author":"E Harlacher","year":"2022","unstructured":"Harlacher E, Wollenhaupt J, Baaten CCFMJ, Noels H (2022) Impact of Uremic Toxins on Endothelial Dysfunction in Chronic Kidney Disease: A Systematic Review. Int J Mol Sci 23(1):531","journal-title":"Int J Mol Sci"},{"key":"10671_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1479-5876-11-263","volume":"11","author":"M El Assar","year":"2013","unstructured":"El Assar M, Ruiz de Adana JC, Angulo J, Pindado Mart\u00ednez ML (2013) Hern\u00e1ndez Mat\u00edas A, Rodr\u00edguez-Ma\u00f1as L. Preserved endothelial function in human obesity in the absence of insulin resistance. J Transl Med 11:263","journal-title":"J Transl Med"},{"issue":"5","key":"10671_CR35","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1210\/er.2007-0006","volume":"28","author":"R Muniyappa","year":"2007","unstructured":"Muniyappa R, Montagnani M, Koh KK, Quon MJ (2007) Cardiovascular actions of insulin. Endocr Rev 28(5):463\u2013491","journal-title":"Endocr Rev"},{"issue":"4","key":"10671_CR36","doi-asserted-by":"publisher","first-page":"e0154003","DOI":"10.1371\/journal.pone.0154003","volume":"11","author":"YE Kang","year":"2016","unstructured":"Kang YE, Kim JM, Joung KH, Lee JH, You BR, Choi MJ et al (2016) The Roles of Adipokines, Proinflammatory Cytokines, and Adipose Tissue Macrophages in Obesity-Associated Insulin Resistance in Modest Obesity and Early Metabolic Dysfunction. PLoS ONE 11(4):e0154003","journal-title":"PLoS ONE"},{"key":"10671_CR37","doi-asserted-by":"crossref","unstructured":"Morawietz H, Brendel H, Diaba-Nuhoho P, Catar R, Perakakis N, Wolfrum C et al (2023) Cross-talk of NADPH oxidases and inflammation in obesity. Antioxid (Basel) 12(8):1589","DOI":"10.3390\/antiox12081589"},{"issue":"6","key":"10671_CR38","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1161\/01.HYP.0000100443.09293.4F","volume":"42","author":"Y Taniyama","year":"2003","unstructured":"Taniyama Y, Griendling KK (2003) Reactive Oxygen Species in the Vasculature. Hypertension 42(6):1075\u20131081","journal-title":"Hypertension"},{"issue":"6","key":"10671_CR39","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamacardio.2023.0957","volume":"8","author":"L Scandalis","year":"2023","unstructured":"Scandalis L, Kitzman DW, Nicklas BJ, Lyles M, Brubaker P, Nelson MB et al (2023) Skeletal Muscle Mitochondrial Respiration and Exercise Intolerance in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol 8(6):575\u2013584","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10671_CR40","first-page":"791","volume":"7","author":"M Farrero","year":"2014","unstructured":"Farrero M, Blanco I, Batlle M, Santiago E, Cardona M, Vidal B et al (2014) Pulmonary Hypertension Is Related to Peripheral Endothelial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Fail 7(5):791\u2013798","journal-title":"Circulation: Heart Fail"},{"issue":"17","key":"10671_CR41","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1161\/CIRCULATIONAHA.117.031608","volume":"137","author":"AU Fayyaz","year":"2018","unstructured":"Fayyaz AU, Edwards WD, Maleszewski JJ, Konik EA, DuBrock HM, Borlaug BA et al (2018) Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction. Circulation 137(17):1796\u20131810","journal-title":"Circulation"},{"issue":"2","key":"10671_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK et al (2021) Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med 384(2):117\u2013128","journal-title":"N Engl J Med"},{"issue":"15","key":"10671_CR43","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F et al (2020) Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 383(15):1436\u20131446","journal-title":"N Engl J Med"},{"issue":"2","key":"10671_CR44","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"Empagliflozin in Patients with Chronic Kidney Disease","year":"2023","unstructured":"Empagliflozin in Patients with Chronic Kidney Disease (2023) N Engl J Med 388(2):117\u2013127","journal-title":"N Engl J Med"},{"issue":"2","key":"10671_CR45","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK et al (2021) Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med 384(2):129\u2013139","journal-title":"N Engl J Med"},{"issue":"24","key":"10671_CR46","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al (2019) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 380(24):2295\u20132306","journal-title":"N Engl J Med"},{"issue":"4","key":"10671_CR47","doi-asserted-by":"publisher","first-page":"e70026","DOI":"10.1002\/pul2.70026","volume":"14","author":"T Satoh","year":"2024","unstructured":"Satoh T, Yaoita N, Higuchi S, Nochioka K, Yamamoto S, Sato H et al (2024) Impact of Sodium-Glucose Co-Transporter-2 Inhibitors on Exercise-Induced Pulmonary Hypertension. Pulm Circ 14(4):e70026","journal-title":"Pulm Circ"},{"issue":"9","key":"10671_CR48","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jamacardio.2024.1914","volume":"9","author":"YNV Reddy","year":"2024","unstructured":"Reddy YNV, Carter RE, Sorimachi H, Omar M, Popovic D, Alogna A et al (2024) Dapagliflozin and Right Ventricular-Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol 9(9):843\u2013851","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10671_CR49","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12933-025-02756-y","volume":"24","author":"A Ovchinnikov","year":"2025","unstructured":"Ovchinnikov A, Potekhina A, Filatova A, Svirida O, Zherebchikova K, Ageev F et al (2025) Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial. Cardiovasc Diabetol 24(1):196","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10671_CR50","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","volume":"42","author":"WT Abraham","year":"2020","unstructured":"Abraham WT, Lindenfeld J, Ponikowski P, Agostoni P, Butler J, Desai AS et al (2020) Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. Eur Heart J 42(6):700\u2013710","journal-title":"Eur Heart J"},{"key":"10671_CR51","doi-asserted-by":"crossref","unstructured":"Volpe S, Vozza A, Lisco G, Fanelli M, Racaniello D, Bergamasco A et al (2024) Sodium-glucose cotransporter 2 inhibitors improve body composition by increasing the skeletal muscle mass\/fat mass ratio in patients with type 2 diabetes: A 52-Week Prospective Real-Life Study. Nutrients 16(22)","DOI":"10.3390\/nu16223841"},{"key":"10671_CR52","doi-asserted-by":"crossref","unstructured":"Adelparvar F, Fakhrolmobasheri M, Qorbani F, Shafie D, Heidarpour M, Nasr M et al (2025) Sodium-glucose cotransporter 2 inhibitors and pulmonary hypertension: a systematic review. Cardiol Rev. Epub ahead of print. PMID: 40183573.","DOI":"10.1097\/CRD.0000000000000888"},{"issue":"10","key":"10671_CR53","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","volume":"148","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Reddy YNV, Braun A, Sorimachi H, Omar M, Popovic D et al (2023) Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial. Circulation 148(10):834\u2013844","journal-title":"Circulation"},{"issue":"1\u20133","key":"10671_CR54","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","volume":"715","author":"A Tahara","year":"2013","unstructured":"Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y et al (2013) Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 715(1\u20133):246\u2013255","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10671_CR55","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/dom.14327","volume":"23","author":"Y He","year":"2021","unstructured":"He Y, Pachori A, Chen P, Ma S, Mendonza AE, Amer A et al (2021) Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2, in patients with chronic kidney disease: A randomized trial. Diabetes Obes Metab 23(5):1182\u20131190","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10671_CR56","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1055\/s-0034-1395609","volume":"47","author":"A Ojima","year":"2015","unstructured":"Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S (2015) Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis. Horm Metab Res 47(9):686\u2013692","journal-title":"Horm Metab Res"},{"key":"10671_CR57","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","volume":"20","author":"L Xu","year":"2017","unstructured":"Xu L, Nagata N, Nagashimada M, Zhuge F, Ni Y, Chen G et al (2017) SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice. EBioMedicine 20:137\u2013149","journal-title":"EBioMedicine"},{"issue":"8","key":"10671_CR58","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/jdi.13491","volume":"12","author":"K Kobayashi","year":"2021","unstructured":"Kobayashi K, Toyoda M, Hatori N, Furuki T, Sakai H, Sato K et al (2021) Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan. J Diabetes Investig 12(8):1408\u20131416","journal-title":"J Diabetes Investig"},{"issue":"1","key":"10671_CR59","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/jdi.13318","volume":"12","author":"K Kobayashi","year":"2021","unstructured":"Kobayashi K, Toyoda M, Hatori N, Furuki T, Sakai H, Umezono T et al (2021) Blood pressure after treatment with sodium-glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score-matched models. J Diabetes Investig 12(1):74\u201381","journal-title":"J Diabetes Investig"},{"issue":"8","key":"10671_CR60","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/dom.14729","volume":"24","author":"T Sen","year":"2022","unstructured":"Sen T, Scholtes R, Greasley PJ, Cherney DZI, Dekkers CCJ, Vervloet M et al (2022) Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND. Diabetes Obes Metab 24(8):1578\u20131587","journal-title":"Diabetes Obes Metab"},{"key":"10671_CR61","doi-asserted-by":"publisher","first-page":"176875","DOI":"10.1016\/j.ejphar.2024.176875","volume":"981","author":"DD Liu","year":"2024","unstructured":"Liu DD, Liu XL, Zheng TF, Li X, Zhao YC, Pan JC et al (2024) Dapagliflozin alleviates right heart failure by promoting collagen degradation by reducing ROS levels. Eur J Pharmacol 981:176875","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10671_CR62","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12933-022-01614-5","volume":"21","author":"J Wu","year":"2022","unstructured":"Wu J, Liu T, Shi S, Fan Z, Hiram R, Xiong F et al (2022) Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling. Cardiovasc Diabetol 21(1):197","journal-title":"Cardiovasc Diabetol"},{"key":"10671_CR63","doi-asserted-by":"publisher","first-page":"155396","DOI":"10.1016\/j.metabol.2022.155396","volume":"140","author":"A Veelen","year":"2023","unstructured":"Veelen A, Andriessen C, Op den Kamp Y, Erazo-Tapia E, de Ligt M, Mevenkamp J et al (2023) Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial. Metabolism 140:155396","journal-title":"Metabolism"},{"issue":"9","key":"10671_CR64","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.2337\/dc24-0470","volume":"47","author":"A Latva-Rasku","year":"2024","unstructured":"Latva-Rasku A, Rebelos E, Tuisku J, Aarnio R, Bhowmik A, Keskinen H et al (2024) SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study. Diabetes Care 47(9):1630\u20131637","journal-title":"Diabetes Care"},{"issue":"3","key":"10671_CR65","doi-asserted-by":"publisher","first-page":"E258","DOI":"10.1152\/ajpendo.00267.2023","volume":"326","author":"LA Jahn","year":"2024","unstructured":"Jahn LA, Hartline LM, Nguyen T, Aylor K, Horton WB, Liu Z et al (2024) Empagliflozin improves vascular insulin sensitivity and muscle perfusion in persons with type 2 diabetes. Am J Physiol Endocrinol Metab 326(3):E258\u2013e67","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"10671_CR66","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/cvr\/cvae257","volume":"121","author":"A Mroueh","year":"2025","unstructured":"Mroueh A, Algara-Suarez P, Fakih W, Gong DS, Matsushita K, Park SH et al (2025) SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO\/ROS imbalance. Cardiovasc Res 121(4):643\u2013657","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10671_CR67","first-page":"575","volume":"4","author":"RP Juni","year":"2019","unstructured":"Juni RP, Kuster DWD, Goebel M, Helmes M, Musters RJP, van der Velden J et al (2019) Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin. JACC: Basic Translational Sci 4(5):575\u2013591","journal-title":"JACC: Basic Translational Sci"},{"issue":"3","key":"10671_CR68","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/dom.16097","volume":"27","author":"DK Kristensen","year":"2025","unstructured":"Kristensen DK, Mose FH, Buus NH, Duus CL, M\u00e5rup FH, Bech JN et al (2025) SGLT2 inhibition improves endothelium-independent vasodilatory function in type 2 diabetes: A double-blind, randomized, placebo-controlled crossover trial. Diabetes Obes Metab 27(3):1123\u20131131","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10671_CR69","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12933-025-02679-8","volume":"24","author":"SGJ Mourmans","year":"2025","unstructured":"Mourmans SGJ, Achten A, Hermans R, Scheepers MJE, D\u2019Alessandro E, Swennen G et al (2025) The effect of empagliflozin on peripheral microvascular dysfunction in patients with heart failure with preserved ejection fraction. Cardiovasc Diabetol 24(1):182","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10671_CR70","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA et al (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375(4):311\u2013322","journal-title":"N Engl J Med"},{"issue":"19","key":"10671_CR71","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA et al (2016) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 375(19):1834\u20131844","journal-title":"N Engl J Med"},{"issue":"13","key":"10671_CR72","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB et al (2017) Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 377(13):1228\u20131239","journal-title":"N Engl J Med"},{"issue":"10","key":"10671_CR73","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD et al (2021) Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med 385(10):896\u2013907","journal-title":"N Engl J Med"},{"issue":"10157","key":"10671_CR74","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB, Sr., Granger CB, Jones NP et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392(10157):1519\u20131529","journal-title":"Lancet"},{"issue":"10193","key":"10671_CR75","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130","journal-title":"Lancet"},{"issue":"9","key":"10671_CR76","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR et al (2019) Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 381(9):841\u2013851","journal-title":"N Engl J Med"},{"issue":"24","key":"10671_CR77","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S et al (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 389(24):2221\u20132232","journal-title":"N Engl J Med"},{"key":"10671_CR78","doi-asserted-by":"crossref","unstructured":"Pfeffer Marc A, Claggett B, Diaz R, Dickstein K, Gerstein Hertzel C, K\u00f8ber Lars V et al (2015) Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 373(23):2247\u20132257","DOI":"10.1056\/NEJMoa1509225"},{"issue":"2","key":"10671_CR79","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G et al (2024) Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 391(2):109\u2013121","journal-title":"N Engl J Med"},{"issue":"4","key":"10671_CR80","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1210\/en.2018-00004","volume":"159","author":"LL Baggio","year":"2018","unstructured":"Baggio LL, Yusta B, Mulvihill EE, Cao X, Streutker CJ, Butany J et al (2018) GLP-1 Receptor Expression Within the Human Heart. Endocrinology 159(4):1570\u20131584","journal-title":"Endocrinology"},{"issue":"1","key":"10671_CR81","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","volume":"40","author":"J Helmst\u00e4dter","year":"2020","unstructured":"Helmst\u00e4dter J, Frenis K, Filippou K, Grill A, Dib M, Kalinovic S et al (2020) Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension. Arterioscler Thromb Vasc Biol 40(1):145\u2013158","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10671_CR82","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1042\/CS20130708","volume":"127","author":"SC Subaran","year":"2014","unstructured":"Subaran SC, Sauder MA, Chai W, Jahn LA, Fowler DE, Aylor KW et al (2014) GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans. Clin Sci (Lond) 127(3):163\u2013170","journal-title":"Clin Sci (Lond)"},{"issue":"7","key":"10671_CR83","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/ejhf.3644","volume":"27","author":"T Krammer","year":"2025","unstructured":"Krammer T, Baier MJ, Hegner P, Zschiedrich T, Lukas D, Wolf M et al (2025) Cardioprotective effects of semaglutide on isolated human ventricular myocardium. Eur J Heart Fail 27(7):1315\u20131325","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10671_CR84","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","volume":"31","author":"BA Borlaug","year":"2025","unstructured":"Borlaug BA, Zile MR, Kramer CM, Baum SJ, Hurt K, Litwin SE et al (2025) Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med 31(2):544\u2013551","journal-title":"Nat Med"},{"issue":"17","key":"10671_CR85","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jacc.2024.08.028","volume":"84","author":"S Verma","year":"2024","unstructured":"Verma S, Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW et al (2024) Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program. J Am Coll Cardiol 84(17):1646\u20131662","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10671_CR86","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/dom.14443","volume":"23","author":"JFE Mann","year":"2021","unstructured":"Mann JFE, Buse JB, Idorn T, Leiter LA, Pratley RE, Rasmussen S et al (2021) Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. Diabetes Obes Metab 23(9):2058\u20132066","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10671_CR87","doi-asserted-by":"publisher","first-page":"e2440286","DOI":"10.1001\/jamanetworkopen.2024.40286","volume":"7","author":"JL Triozzi","year":"2024","unstructured":"Triozzi JL, Yu Z, Giri A, Chen HC, Wilson OD, Ferolito B et al (2024) GLP1R Gene Expression and Kidney Disease Progression. JAMA Netw Open 7(10):e2440286","journal-title":"JAMA Netw Open"},{"key":"10671_CR88","doi-asserted-by":"publisher","first-page":"1551136","DOI":"10.3389\/fimmu.2025.1551136","volume":"16","author":"L Peng","year":"2025","unstructured":"Peng L, Lai W, Yu S, Li Q, Jiang X, Chen G (2025) GLP-1 and glucagon receptor dual agonism ameliorates kidney allograft fibrosis by improving lipid metabolism. Front Immunol 16:1551136","journal-title":"Front Immunol"},{"issue":"1","key":"10671_CR89","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12929-019-0496-y","volume":"26","author":"J Wang","year":"2019","unstructured":"Wang J, Yu M, Xu J, Cheng Y, Li X, Wei G et al (2019) Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension. J Biomed Sci 26(1):6","journal-title":"J Biomed Sci"},{"issue":"4","key":"10671_CR90","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.jtcvs.2017.10.085","volume":"155","author":"JN Roan","year":"2018","unstructured":"Roan JN, Hsu CH, Fang SY, Tsai HW, Luo CY, Huang CC et al (2018) Exendin-4 improves cardiovascular function and survival in flow-induced pulmonary hypertension. J Thorac Cardiovasc Surg 155(4):1661\u20139e4","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"10671_CR91","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/jcsm.13445","volume":"15","author":"A Pandey","year":"2024","unstructured":"Pandey A, Patel KV, Segar MW, Ayers C, Linge J, Leinhard OD et al (2024) Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial. J Cachexia Sarcopenia Muscle 15(3):1072\u20131083","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"20","key":"10671_CR92","first-page":"9908","volume":"27","author":"J Xiang","year":"2023","unstructured":"Xiang J, Ding XY, Zhang W, Zhang J, Zhang YS, Li ZM et al (2023) Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults. Eur Rev Med Pharmacol Sci 27(20):9908\u20139915","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"10671_CR93","doi-asserted-by":"publisher","first-page":"H370","DOI":"10.1152\/ajpheart.00257.2024","volume":"327","author":"B Park","year":"2024","unstructured":"Park B, Krishnaraj A, Teoh H, Bakbak E, Dennis F, Quan A et al (2024) GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes. Am J Physiol Heart Circ Physiol 327(2):H370\u2013h6","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"10671_CR94","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/bph.14534","volume":"176","author":"M Bangshaab","year":"2019","unstructured":"Bangshaab M, Gutierrez A, Huynh KD, Knudsen JS, Arcanjo DDR, Petersen AG et al (2019) Different mechanisms involved in liraglutide and glucagon-like peptide-1 vasodilatation in rat mesenteric small arteries. Br J Pharmacol 176(3):386\u2013399","journal-title":"Br J Pharmacol"},{"issue":"15","key":"10671_CR95","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al (2014) Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med 370(15):1383\u20131392","journal-title":"N Engl J Med"},{"issue":"4","key":"10671_CR96","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1002\/ehf2.13969","volume":"9","author":"M Choy","year":"2022","unstructured":"Choy M, Liang W, He J, Fu M, Dong Y, He X et al (2022) Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment. ESC Heart Fail 9(4):2567\u20132575","journal-title":"ESC Heart Fail"},{"issue":"23","key":"10671_CR97","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P et al (2020) Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 383(23):2219\u20132229","journal-title":"N Engl J Med"},{"issue":"24","key":"10671_CR98","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P et al (2021) Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 385(24):2252\u20132263","journal-title":"N Engl J Med"},{"issue":"6","key":"10671_CR99","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A et al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43(6):474\u2013484","journal-title":"Eur Heart J"},{"key":"10671_CR100","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fphys.2015.00269","volume":"6","author":"MA Silva","year":"2015","unstructured":"Silva MA, Bruder-Nascimento T, Cau SB, Lopes RA, Mestriner FL, Fais RS et al (2015) Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO\/GC signaling. Front Physiol 6:269","journal-title":"Front Physiol"},{"issue":"4","key":"10671_CR101","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune J, Beyhoff N, Smeir E, Chudek R, Blumrich A, Ban Z et al (2018) Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone\u2019s Antifibrotic Activity. Hypertension 71(4):599\u2013608","journal-title":"Hypertension"},{"issue":"1","key":"10671_CR102","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, B\u00e4rfacker L et al (2014) Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 64(1):69\u201378","journal-title":"J Cardiovasc Pharmacol"},{"issue":"18","key":"10671_CR103","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):e895\u2013e1032","journal-title":"Circulation"},{"issue":"11","key":"10671_CR104","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","volume":"77","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G et al (2021) Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. J Am Coll Cardiol 77(11):1397\u20131407","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10671_CR105","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau J, Bloch P, Sch\u00e4ffer L, Pettersson I, Spetzler J, Kofoed J et al (2015) Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem 58(18):7370\u20137380","journal-title":"J Med Chem"},{"issue":"4","key":"10671_CR106","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK et al (2024) KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 105(4):S117\u2013S314","journal-title":"Kidney Int"},{"issue":"12","key":"10671_CR107","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM et al (2022) Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 45(12):3075\u20133090","journal-title":"Diabetes Care"},{"issue":"11","key":"10671_CR108","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","volume":"12","author":"R Patel","year":"2024","unstructured":"Patel R, Wadid M, Makwana B, Kumar A, Khadke S, Bhatti A et al (2024) GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors. JACC Heart Fail 12(11):1814\u20131826","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10671_CR109","first-page":"236","volume":"56","author":"JP Ferreira","year":"2025","unstructured":"Ferreira JP, Oliveira AC, Vasques-Novoa F, Leite AR, Mendon\u00e7a L, Zannad F et al (2025) Mineralocorticoid Receptor Antagonist Combined with SGLT2 Inhibitor versus SGLT2 Inhibitor Alone in Chronic Kidney Disease: A Meta-Analysis of Randomized Trials. Am J Nephrol 56(2):236\u2013242","journal-title":"Am J Nephrol"},{"key":"10671_CR110","doi-asserted-by":"crossref","unstructured":"Cooper ME, van Raalte DH (2025) GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. J Clin Investig 135(21):e194749","DOI":"10.1172\/JCI194749"},{"issue":"2","key":"10671_CR111","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1159\/000534808","volume":"55","author":"KR Tuttle","year":"2024","unstructured":"Tuttle KR, Rossing P, Hauske SJ, Cronin L, Hussain J, de Zeeuw D et al (2024) Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease. Am J Nephrol 55(2):262\u2013272","journal-title":"Am J Nephrol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10671-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10671-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10671-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:02:28Z","timestamp":1789963348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10671-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10671"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10671-x","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"5 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"108"}}